Amerikanische Gesellschaft für Hirudotherapie

Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma

Translational immunology published in Science Translational Medicine (2016)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSicherheit & InfektionskontrolleSpeichel-PharmakologieNavarro S et al. · Science translational medicine, 2016

Abstract

In the developed world, declining prevalence of some parasitic infections correlates with increased incidence of allergic and autoimmune disorders. Moreover, experimental human infection with some parasitic worms confers protection against inflammatory diseases in phase 2 clinical trials. Parasitic worms manipulate the immune system by secreting immunoregulatory molecules that offer promise as a novel therapeutic modality for inflammatory diseases. We identify a protein secreted by hookworms, anti-inflammatory protein-2 (AIP-2), that suppressed airway inflammation in a mouse model of asthma, reduced expression of costimulatory markers on human dendritic cells (DCs), and suppressed proliferation ex vivo of T cells from human subjects with house dust mite allergy. In mice, AIP-2 was primarily captured by mesenteric CD103+ DCs and suppression of airway inflammation was dependent on both DCs and Foxp3+ regulatory T cells (Tregs) that originated in the mesenteric lymph nodes (MLNs) and accumulated in distant mucosal sites. Transplantation of MLNs from AIP-2-treated mice into naïve hosts revealed a lymphoid tissue conditioning that promoted Treg induction and long-term maintenance. Our findings indicate that recombinant AIP-2 could serve as a novel curative therapeutic for allergic asthma and potentially other inflammatory diseases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdultAncylostomatoideaAnimalsAntigens, CDAsthmaCell ProliferationCytokinesDendritic CellsDisease Models, AnimalFemaleHelminth ProteinsHumans

Zusammenfassung

Hookworm recombinant protein AIP-2 induces regulatory T cells and suppresses experimental asthma — parallel to potential immunomodulatory leech salivary proteins.

Warum dies für die Hirudotherapie relevant ist

This study identified a recombinant protein (AIP-2) secreted by hookworms that suppressed airway inflammation in a mouse asthma model, reduced costimulatory marker expression on human dendritic cells, and inhibited T-cell proliferation in samples from human allergy subjects. The mechanism involved CD103+ dendritic cells and Foxp3+ regulatory T cells, with mesenteric lymph node transplantation revealing long-term lymphoid tissue conditioning. While this work is conceptually relevant to the broader field of parasite-derived immunomodulatory molecules—a category that includes leech secretome components—the study involves no leeches whatsoever, focusing entirely on hookworm biology. ASH members may find the paradigm of parasite-secreted therapeutic proteins informative by analogy, but the abstract provides no direct evidence or findings applicable to hirudotherapy or leech-derived compounds.

Zitation

Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma.

Navarro S et al. · Science translational medicine, 2016

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.